byĀ Sally Grosvenor, Larissa Chirkova, Scott Standfield, and Danny Voorhamme
Volume 6, IssueĀ 4 (Winter 2007)
With the continued growth of the biopharmaceutical market, the cell culture industry has seen a major shift away from the use of serum and other animal-derived supplements in the manufacture of biopharmaceuticals. Indeed, supporting guidance from the EMEA and FDA for the manufacture of biopharmaceuticals and medical devices encourages the use of “animal-free” components. The key driver for this can be attributed to the increased concern with contamination from adventitious agents such as transmissible encephalopathiesā¦
Citation:
Grosvenor S, Chirkova L, Standfield S, Voorhamme D. Enhanced CHO Cell Performance With a Combination of CellPrimeā¢ Recombinant Transferrin and LONGR3IGF-1. BioProcess J, 2007; 6(4): 45-51.Ā http://dx.doi.org/10.12665/J64.Grosvenor